Abstract:Abstract Objectives Aspirin, or acetylsalicylic acid (ASA), can lead to gastrointestinal mucosal injury through disruption of its protective phospholipid bilayer, underscoring the need for ASA formulations with a more favorable safety profile while maintaining an effective pharmacologic profile. A liquid formulation using a novel pharmaceutical lipid aspirin complex (PL-ASA) has been designed to prevent the disruption of the protective mucosal bilayer. We sought to determine the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of PL-ASA compared with traditional, immediate release aspirin (IR-ASA). Methods In this active-control crossover study, 16 healthy volunteers were randomized to receive a single dose of either IR-ASA 325 mg or PL-ASA 325 mg in a sequential fashion with a 2-week washout period between treatment assignments. The primary objectives of the study were to assess PK (i.e., plasma salicylic acid levels) and PD (i.e., serum thromboxane B2 levels) bioequivalence over a 24–hour period after drug administration, of PL-ASA and IR-ASA using established criteria. Results The PK parameter values were similar for PL-ASA and IR-ASA, with median AUC 0-t and Cmax values nominally higher for PL-ASA. Log-transformed PK parameters meeting FDA-criteria for bioequivalence (80% to 125%) are provided in the Table. Serum thromboxane B2 levels were similar for PL-ASA and IR-ASA, with Cmin values below 3.1 ng/mL (cut-off associated with decreased cardiovascular events) for both drugs. Both drugs also showed >99% inhibition of serum thromboxane B2 levels (≥95% inhibition represents the cut-off to define aspirin responders). Several secondary PK/PD parameters showed similarities between the two drugs (data not shown). Overall, these findings support functional and clinical equivalence between PL-ASA and IR-ASA. PK Results Parameter Ratio (PL-ASA/IR-ASA) 90% Confidence Interval AUC0-t 96.51 89.24, 104.37 Cmax 103.73 92.06, 116.89 Conclusions PL-ASA's novel liquid formulation has similar PK and PD performance compared with IR-ASA. The improved endoscopic safety profile of PL-ASA coupled with its pharmacologic efficacy equivalent to IR-ASA may result in an improved benefit-risk performance, warranting evaluation in future trials. Acknowledgement/Funding PLx Pharma, Inc.

Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy.

Modification of sodium aescinate into a safer, more stable and effective water-soluble drug by liposome-encapsulation: an in vitro and in vivo study

Development of Self-Administered Formulation to Improve the Bioavailability of Leuprorelin Acetate

Intranasal delivery of α-asarone to the brain with lactoferrin-modified mPEG-PLA nanoparticles prepared by premix membrane emulsification

Pilot-Scale Synthesis and Purification of α-Asaronol for Antiepileptic Drug Development

[Study on Alpha-Asarone Reservoir-Type Patch].

Preparation and Evaluation of Artemether Liposomes for Enhanced Anti-Tumor Therapy

Preparation and in vivo evaluation of an intravenous emulsion loaded with an aprepitant-phospholipid complex

Development of drug-in-adhesive transdermal patch for α-asarone and in vivo pharmacokinetics and efficacy evaluation.

Lipid emulsion as a drug delivery system for breviscapine: Formulation development and optimization

Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study

Injectable leonurine nanocrystal-loaded microspheres for long-term hyperlipidemia management.

An oil-free microemulsion for intravenous delivery of diallyl trisulfide: formulation and evaluation.

Experimental Study on Controlled Release of As_2O_3 - Lipiodol Suspension and As_2O_3- Lipiodol Emulsion

P1935Pharmacokinetic and pharmacodynamic assessment of a lipid-based aspirin formulation: results of a prospective, randomised, crossover study

Parenteral formulation of an antileishmanial drug candidate--tackling poor solubility, chemical instability, and polymorphism

Hot "Dissolving" Extrusion of Lurasidone with Natural Liquid Small Molecule for Amorphous Solid Dispersion Based Self‐Assembled Submicron Emulsion

Advances in intravenous lipid emulsions

Preparation and Evaluation of Lipid Emulsion Containing 13 Vitamins for Injection Without Anaphylactoid Reactions

Ameliorating Vascular Endothelial Injury for Lipolysacharide-Induced Via Mitochondrial Targeting Function of Octaarginine-Modified Essential Oil from Fructus Alpiniae Zerumbet (EOFAZ) Lipid Microspheres

Improving the targeting and therapeutic efficacy of anastrazole for the control of breast cancer: In vitro and in vivo characterization